SAN FRANCISCO, Dec. 06, 2016 -- BioQ Pharma Incorporated, a specialty pharmaceutical company, today announced the signing of a strategic distribution, supply and development agreement to commercialize three infusion pharmaceuticals in the United Kingdom and the Republic of Ireland with Galen Limited, a specialty pharmaceutical company marketing products within the UK, Ireland, Europe and the US in therapeutic areas such as pain management, gastroenterology and female health.
"We are delighted to partner with Galen Limited. Galen has a distinguished history in commercializing pharmaceutical products internationally. Their experience in launching innovative combination products into hospitals in the UK and Ireland will be invaluable to our collective commercial efforts moving forward,” said Josh Kriesel, President and CEO of BioQ Pharma.
About BioQ Pharma
BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Cipla, Lee's Pharm, Lunatus, Galen Limited, and West Pharmaceutical Services.
Company Contact Information: Josh Kriesel President and CEO 415-336-6496 Ron Pauli Chief Financial Officer 415-889-7707 Walter Cleymans Vice President Europe Phone: +32 474 (053) 253 Media: Stephanie Carrington Integrated Corporate Relations, Inc. (ICR) 646-277-1282


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Anta Sports Expands Global Footprint With Strategic Puma Stake
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Washington Post Publisher Will Lewis Steps Down After Layoffs
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



